Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biora Therapeutics (BIOR)
OTHER OTC:BIOR
Holding BIOR?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$3.5Last Year’s EPS
-$6.25Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -75.90%
|Next Earnings Date:Mar 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in clinical trials and partnerships, especially for the NaviCap and BioJet platforms, alongside strong financial backing from investors. However, the company faces operational challenges with legacy costs and high operating expenses.Company Guidance
During the Biora Therapeutics Q2 2024 earnings call, the company provided guidance on several key metrics and future plans. The focus was on the successful Phase I clinical trial for the BT-600 program using the NaviCap platform, targeting ulcerative colitis, which demonstrated promising pharmacokinetic (PK) profiles and tissue drug exposure. The company reported significant lower systemic drug levels, 3 to 4 times lower than traditional oral delivery, potentially reducing toxicity risks. Biora also announced active partnership discussions for the BioJet platform, aimed at improving the oral delivery of large molecules, with a goal to finalize at least one partnership in 2024. Financially, the company reported operating expenses of $14.5 million for the quarter, excluding stock-based compensation, and a core OpEx of $11.7 million. They have secured an additional $16 million funding from investors, structured as a bridge to anticipated pharma partnerships.Successful Phase I Clinical Trial for BT-600
The NaviCap platform demonstrated successful delivery of tofacitinib directly to colon tissue in ulcerative colitis patients, achieving a PK profile consistent with colon drug delivery and significantly lower systemic levels, potentially reducing toxicity risks.
Progress in BioJet Platform Partnerships
Active partnership discussions with multiple large pharma companies for the BioJet platform, with anticipated completion of at least one partnership in the near term, highlighting industry interest in the technology.
Strong Financial Support
Secured an additional $16 million in capital from existing investors, structured to provide funding in $4 million increments as needed, ensuring financial stability while pursuing partnerships.
BioJet Platform Performance
BioJet platform demonstrated high bioavailability of approximately 40% for large molecules, comparable to subcutaneous injection standards, promising a non-invasive alternative to needle-based delivery systems.
---
BIOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BIOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $2.49 | $2.38 | -4.42% |
| Aug 12, 2024 | $5.83 | $6.70 | +14.92% |
| May 15, 2024 | $7.15 | $7.37 | +3.08% |
| Mar 26, 2024 | $13.30 | $11.70 | -12.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biora Therapeutics (BIOR) report earnings?
Biora Therapeutics (BIOR) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Biora Therapeutics (BIOR) earnings time?
Biora Therapeutics (BIOR) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIOR EPS forecast?
BIOR EPS forecast for the fiscal quarter 2024 (Q4) is -$3.5.
---